Egetis Therapeutics AB (publ) EGTX.ST
Composite 48/100; the shares have moved about 55% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 8/100 — a strong mark against it.
Growth ranks 91/100 — a strong point in its favour. Momentum ranks 83/100 — a strong point in its favour. Balance-sheet strength ranks 73/100 — a moderate point in its favour.
Valuation ranks 8/100 — a strong mark against it. Quality ranks 13/100 — a strong mark against it.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.